Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.58 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | NOS2 | P35228 | 6/20 | 0.52 |
| ▸ | NOS1 | P29475 | 5/20 | 0.52 |
| ▸ | NOS3 | P29474 | 4/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.50 |
| ▸ | GABRD | O14764 | 2/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17281360 | 1.00 | GSR (0.58) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL4435999 | 1.00 | GSR (0.58) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL433668 | 1.00 | GSR (0.58) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL16577962 | 0.95 | GSR (0.64) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL13369016 | 0.95 | GSR (0.64) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL15987065 | 0.87 | GSR (0.71) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL13703207 | 0.87 | GSR (0.50) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29289 | 0.87 | GSR (0.71) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL10135848 | 0.87 | GSR (0.71) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL29291 | 0.87 | GSR (0.71) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2010524472-A | — | — | 2010-07-22 | — | — | JP | claimed |
| EP-2147116-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | Enzon Pharmaceuticals, Inc. (US) | 2010-01-27 | — | — | EP | claimed |
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2008131208-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ENZON PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| CN-1237171-C | Enzymatic deprotection of amines and hydroxides | BRISTOL MYERS SQUIBB CO (US) | 2006-01-18 | — | — | CN | claimed |
| US-6828119-B2 | Deprotecting a hydroxide or amine; obtain sample, incubate with enzyme, remoe protecting group, recover amine | BRISTOL MYERS SQUIBB COMPANY | 2004-12-07 | — | — | US | claimed |
| CN-1484695-A | Enzymatic deprotection of amines and hydroxides | ����˹�ж�-����˹˹������˾ | 2004-03-24 | — | — | CN | claimed |
| EP-1348025-A2 | ENZYMATIC DEPROTECTION OF AMINES AND HYDROXIDES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | claimed |
| US-20020123110-A1 | Enzymatic deprotection of amines and hydroxides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-05 | — | — | US | claimed |
| WO-2002053724-A2 | ENZYMATIC DEPROTECTION OF AMINES AND HYDROXIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-11 | — | — | WO | claimed |
| WO-2025122670-A1 | FORMULATIONS FOR DUAL VEGF/IL-6 INHIBITORS, ANTI-VEGF ANTIBODIES, AND CONJUGATES THEREOF | KODIAK SCIENCES INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250154198-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2025-05-15 | — | — | US | disclosed |
| EP-4440592-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-10-09 | — | — | EP | disclosed |
| CN-118354781-A | Peptide inhibitors of interleukin-23 receptor | 西兰制药公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023217679-A1 | MASS-TAG LABELING OF THE CELLULAR SECRETOME | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-11-16 | — | — | WO | disclosed |
| US-4665052-A | HOMOPHENYLALANINE, HYPOTENSIVES, ANTIALDOSTERONES | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0158057-A1 | Salts of oxazaphosphorine derivatives | ASTA Pharma AG (DE) | 1985-10-16 | — | — | EP | disclosed |
| EP-0156320-A2 | Renin inhibitors containing homophe 8 and a C-terminal amide cycle | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
| US-4485099-A | HYPOTENSIVE AGENTS/,ANTIALDOSTERONES | MERCK & CO., INC. (US) | 1984-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047271-A1 | STABLE RECOMBINANT ADENOSINE DEAMINASE | ADA, CDA, DCTD | GSR 329/4885ARG2 1011/4885ARG1 1904/4885 |
| US-20250154198-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | IL23R, IL1RN, IL33 | GSR 2148/4885ARG2 2942/4885ARG1 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.